Pricing Log in Create free account

CorMedix Inc (CRMD) vs Phathom Pharmaceuticals, Inc. (PHAT)

CorMedix Inc and Phathom Pharmaceuticals, Inc. are both Biotechnology companies. CorMedix Inc and Phathom Pharmaceuticals, Inc. are of similar size ($606.8M and $581.5M). Phathom Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; CorMedix Inc trades at 3.0×. CorMedix Inc grew revenue faster over the last twelve months: 280.5% against 110.2%. CorMedix Inc has the higher net margin (40.5% vs −41.3%) and the higher return on invested capital (38.8% vs 0.00%). Across the 16 metrics below, CorMedix Inc leads on 13 and Phathom Pharmaceuticals, Inc. on 3.

Valuation

Metric CRMD PHAT Biotechnology median
P/E 3.01 n/m 8.50
P/S 1.23 2.42 9.71
P/B 1.24 n/m 2.13
Price to free cash flow 2.27 n/m 20.82
EV/EBITDA 1.81 n/m 0.64
EV/Sales 0.99 2.39 9.21
Earnings yield 33.20% (18.50%) (33.15%)
Free cash flow yield 43.97% (6.37%) (25.50%)

Profitability

Metric CRMD PHAT Biotechnology median
Gross margin 82.78% 82.92% 65.16%
Operating margin 46.95% (16.96%) 0.00%
Net margin 40.49% (41.34%) 0.00%
Free cash flow margin 54.17% (15.40%) 0.00%
Return on equity 54.93% 26.42% (56.36%)
Return on assets 32.36% (34.32%) (48.04%)
Return on invested capital 38.84% 0.00% 0.00%

Growth

Metric CRMD PHAT Biotechnology median
Revenue growth (TTM) 280.50% 110.16% 6.02%
EPS growth (last fiscal year) 780.00% 42.72% 30.26%
Revenue growth, 5-year CAGR 305.79% — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRMD PHAT Biotechnology median
Debt to equity 0.32 (0.48) 0.00
Current ratio 2.56 1.92 4.72
Net debt to EBITDA (0.02) (0.51) 0.96

Dividend

Metric CRMD PHAT Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRMD PHAT Biotechnology median
Market cap 581.47m 606.76m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack